Condition

Stage IIIA Lung Non-Small Cell Cancer AJCC v7

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 19 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials19

Recruiting1

Common interventions25

Lead sponsors shown5

Clinical trials

19 shown

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 TherapyNCT04892953 · 2021-07-07

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung CancerNCT03158129 · 2017-06-16

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung CancerNCT02503722 · 2017-03-23

ACTIVE_NOT_RECRUITING

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid TumorsNCT02498613 · 2016-08-31

ACTIVE_NOT_RECRUITING

Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerNCT02520778 · 2016-08-30

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)NCT02595944 · 2016-07-22

ACTIVE_NOT_RECRUITING

FLARE RT for Patients With Stage IIB-IIIB Non-small Cell Lung Cancer: Personalizing Radiation Therapy Using PET/CT and SPECT/CT ImagingNCT02773238 · 2016-05-20

Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ MalignanciesNCT02706392 · 2016-03-16

Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung CancerNCT02535325 · 2015-09-30

Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation TherapyNCT02452463 · 2015-06-29

Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)NCT02193282 · 2015-02-11

ACTIVE_NOT_RECRUITING

Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)NCT02194738 · 2014-09-26

ACTIVE_NOT_RECRUITING

Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01912625 · 2013-10-28

Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung CancerNCT01507428 · 2012-02-22

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT01386385 · 2011-06-20

ACTIVE_NOT_RECRUITING

Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung CancerNCT01413750 · 2010-11-08

Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By SurgeryNCT00324805 · 2007-07-19

Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by SurgeryNCT00334815 · 2006-06-15

ACTIVE_NOT_RECRUITING

Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following SurgeryNCT00254384 · 2005-10-05

Common interventions

Leading sponsors

National Cancer Institute (NCI)13 M.D. Anderson Cancer Center3 Fred Hutchinson Cancer Center1 Roswell Park Cancer Institute1 University of Washington1

Trial status mix

ACTIVE_NOT_RECRUITING7

COMPLETED7

TERMINATED4

RECRUITING1

Phase mix

PHASE29

PHASE17

PHASE33

NA1

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.